Abatacept for the Treatment of Refractory Juvenile Dermatomyositis

Trial Profile

Abatacept for the Treatment of Refractory Juvenile Dermatomyositis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Dermatomyositis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 06 Nov 2015 New trial record
    • 05 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top